Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.
IPO Year: 2014
Exchange: NYSE
Website: catalent.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/16/2023 | $45.00 → $53.00 | Neutral → Outperform | Robert W. Baird |
| 9/5/2023 | $62.00 | Hold → Buy | Argus |
| 7/20/2023 | $43.00 | Equal Weight | Wells Fargo |
| 7/5/2023 | $45.00 | Neutral | JP Morgan |
| 6/14/2023 | $45.00 → $44.00 | Buy → Hold | Jefferies |
| 5/22/2023 | $90.00 → $45.00 | Overweight → Neutral | JP Morgan |
| 5/15/2023 | $55.00 → $29.00 | Buy → Hold | Deutsche Bank |
| 5/8/2023 | $28.00 | Neutral → Underperform | BofA Securities |
| 4/17/2023 | $82.00 → $53.00 | Outperform → Neutral | Robert W. Baird |
| 4/14/2023 | Outperform → Mkt Perform | William Blair |
Adds three new directors with deep expertise across biopharma and life sciences Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings' ownership. Alessandro Maselli, President and CEO, and Board member of Catalent, said "I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech customers. Susan, Marie-France and Tim are each accomplished leaders who bring
NEW YORK, Dec. 18, 2024 /PRNewswire/ -- S&P MidCap 400 constituent Lennox International Inc. (NYSE:LII) will replace Catalent Inc. (NYSE:CTLT) in the S&P 500, and BILL Holdings Inc. (NYSE:BILL) will replace Lennox International in the S&P MidCap 400 effective prior to the opening of trading on Monday, December 23. Novo Holdings A/S has acquired Catalent in a deal that closed today, December 18. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 23, 2024 S&P 500 Addition Lennox International LII Industrials Dec 23, 2024 S&P 500 Deletion Catalent CTLT Health
Catalent to Strengthen its Leading Position as a Global Service Provider for the Pharma and Biotech Industry under Private Ownership Catalent, Inc. ("Catalent"), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S ("Novo Holdings"), a global life sciences investment firm, today announced that Novo Holdings has completed its previously announced acquisition of Catalent in an all-cash transaction with a total enterprise value of approximately $16.5 billion. Alessandro Maselli, who will remain President and Chief Executive Officer of Catalent, said, "The completion of this transaction marks a significant milestone for Catalent.
Transaction Expected to Close in the Coming Days Catalent, Inc. (("Catalent, NYSE:CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S ("Novo Holdings"), a global life sciences investment firm, today announced that the companies have fulfilled all regulatory closing conditions for their pending transaction. The companies now expect to close the transaction in the coming days. "Today represents an important step in our transition to private ownership under Novo Holdings, a leading life sciences investment firm," said Alessandro Maselli, President and Chief Executive Officer of Catalent. "As we approach transaction close
Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T
Transaction Expected to Close Towards the End of Calendar Year 2024 Catalent, Inc. (("Catalent, NYSE:CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S ("Novo Holdings"), a global life sciences investment firm, today announced that the European Commission (EC) has granted unconditional approval for the pending transaction under which Novo Holdings will acquire Catalent. "We are pleased to have received European Commission approval, which is a significant milestone toward completing our pending transaction with Novo Holdings," said Alessandro Maselli, President and Chief Executive Officer of Catalent. "I am deeply gra
Q1'25 net revenue of $1.02 billion increased 4% as reported and in constant currency(1), compared to Q1'24. Q1'25 net revenue, excluding COVID revenue of ~$30 million in Q1'25 and ~$100 million in Q1'24, increased 13% compared to Q1'24. Q1'25 net loss of $(129) million. Q1'25 Adjusted EBITDA(1) of $125 million increased 11% as reported, or 10% in constant currency, compared to Q1'24. (1) See "Non-GAAP Financial Measures" below and the GAAP to non-GAAP reconciliation provided later in this release. Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the first quarter of fisc
Committed to Continuing to Serve Customers and Patients as a Leading Global, Independent, Full-Service CDMO Post-Close Alessandro Maselli to Remain President and CEO of Catalent Post-Close Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today issued the following open letter to customers: To Catalent's Valued Customers, I want to correct a few key inaccuracies that have been reported in the press regarding Novo Holdings' pending acquisition of Catalent and reiterate that we are, and will continue to be, driven by our mission to develop, manufacture and supply products that help people live better and healthier li
Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ to Ardena, a Contract Development and Manufacturing Organization (CDMO) with locations in Belgium, Spain, the Netherlands and Sweden. Financial details of the agreement, which is expected to close in early 2025, have not been disclosed. The Somerset facility also houses Catalent's corporate headquarters, which in the near term will remain at the Somerset site during a transition period before shifting to a new locati
Q4'24 net revenue of $1.30 billion increased 23% as reported, or 24% in constant currency, compared to Q4'23. Organic, constant-currency net revenue increased 24%, compared to Q4'23. Q4'24 net revenue, excluding COVID-related revenue of ~$70 million in Q4'23 and ~$30 million in Q4'24, increased 29% compared to Q4'23. Fiscal 2024 net revenue of $4.38 billion increased 3% as reported, or 2% in constant currency, compared to fiscal 2023. Organic, constant-currency net revenue increased 1% compared to FY'23. FY'24 net revenue, excluding COVID-related revenue of ~$630 million in FY'23 and ~$260 million in FY'24, increased 13% compared to FY'23. Q4'24 net earnings of $23 million
15-12G - Catalent, Inc. (0001596783) (Filer)
POSASR - Catalent, Inc. (0001596783) (Filer)
S-8 POS - Catalent, Inc. (0001596783) (Filer)
S-8 POS - Catalent, Inc. (0001596783) (Filer)
S-8 POS - Catalent, Inc. (0001596783) (Filer)
8-K - Catalent, Inc. (0001596783) (Filer)
25-NSE - Catalent, Inc. (0001596783) (Subject)
8-K - Catalent, Inc. (0001596783) (Filer)
8-K - Catalent, Inc. (0001596783) (Filer)
10-Q - Catalent, Inc. (0001596783) (Filer)
SC 13G/A - Catalent, Inc. (0001596783) (Subject)
SC 13G/A - Catalent, Inc. (0001596783) (Subject)
SC 13G/A - Catalent, Inc. (0001596783) (Subject)
SC 13G/A - Catalent, Inc. (0001596783) (Subject)
SC 13G - Catalent, Inc. (0001596783) (Subject)
SC 13G/A - Catalent, Inc. (0001596783) (Subject)
SC 13G/A - Catalent, Inc. (0001596783) (Subject)
SC 13G/A - Catalent, Inc. (0001596783) (Subject)
SC 13G/A - Catalent, Inc. (0001596783) (Subject)
SC 13G/A - Catalent, Inc. (0001596783) (Subject)
Q1'25 net revenue of $1.02 billion increased 4% as reported and in constant currency(1), compared to Q1'24. Q1'25 net revenue, excluding COVID revenue of ~$30 million in Q1'25 and ~$100 million in Q1'24, increased 13% compared to Q1'24. Q1'25 net loss of $(129) million. Q1'25 Adjusted EBITDA(1) of $125 million increased 11% as reported, or 10% in constant currency, compared to Q1'24. (1) See "Non-GAAP Financial Measures" below and the GAAP to non-GAAP reconciliation provided later in this release. Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the first quarter of fisc
Q4'24 net revenue of $1.30 billion increased 23% as reported, or 24% in constant currency, compared to Q4'23. Organic, constant-currency net revenue increased 24%, compared to Q4'23. Q4'24 net revenue, excluding COVID-related revenue of ~$70 million in Q4'23 and ~$30 million in Q4'24, increased 29% compared to Q4'23. Fiscal 2024 net revenue of $4.38 billion increased 3% as reported, or 2% in constant currency, compared to fiscal 2023. Organic, constant-currency net revenue increased 1% compared to FY'23. FY'24 net revenue, excluding COVID-related revenue of ~$630 million in FY'23 and ~$260 million in FY'24, increased 13% compared to FY'23. Q4'24 net earnings of $23 million
Q3'24 net revenue of $1.07 billion increased 4% as reported, or 3% in constant currency(1), compared to Q3'23. Q3'24 net revenue, excluding COVID-related revenue of ~$120 million in Q3'23 and ~$60 million in Q3'24, increased 11% compared to Q3'23. Q3'24 net loss of $(101) million compared to $(227) million of net loss in Q3'23. Q3'24 Adjusted EBITDA(1) of $163 million increased 55% as reported, or 53% in constant currency, compared to Q3'23. (1) See "Non-GAAP Financial Measures" below and the GAAP to non-GAAP reconciliation provided later in this release. Catalent, Inc. (NYSE:CTLT) ("Catalent"), the leader in enabling the development and supply of better treatments for patien
Q2'24 net revenue of $1.03 billion decreased 10% as reported, or 11% in constant currency(1), compared to Q2'23. Q2'24 net revenue, excluding COVID-related revenue of ~$260 million in Q2'23 and ~$75 million in Q2'24, increased 8% compared to Q2'23. Q2'24 net loss of $(204) million compared to $81 million of net income in Q2'23 due primarily to a decline in COVID-related demand. Q2'24 Adjusted EBITDA(1) of $124 million decreased 56% as reported, or 57% in constant currency, compared to Q2'23. Raised $600 million in term loans and used proceeds to pay down revolver; ~$1.3 billion in total available liquidity as of December 31, 2023. Announced on February 5, 2024 that No
Catalent Stockholders to Receive $63.50 Per Share in Cash, Representing a 47.5% Premium to the 60-day Volume-Weighted Average Price as of February 2, 2024 Catalent, Inc. (NYSE:CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, today announced that they have entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis. Transaction Overview Novo Holdings will acquire all outstanding shares
Q1'24 net revenue of $982 million decreased 4% as reported, or 6% in constant currency(1), compared to Q1'23. Organic, constant-currency net revenue decreased by 8%, compared to Q1'23. Q1'24 net revenue, excluding COVID revenue of ~$185 million in Q1'23 and ~$100 million in Q1'24, increased 5% compared to Q1'23. Q1'24 net loss of $(715) million, includes non-cash goodwill impairment charges of $700 million. Q1'24 Adjusted EBITDA(1) of $115 million decreased 38% as reported, or 39% in constant currency, compared to Q1'23. Reaffirming FY'24 financial guidance range, which includes net revenue of $4.3 billion to $4.5 billion and Adjusted EBITDA(1) of $680 million to $760 milli
Q4'23 net revenue of $1.07 billion decreased (17)% as reported, or (17)% in constant currency, compared to Q4'22. Organic, constant-currency net revenue decreased (19)%, compared to Q4'22. Fiscal 2023 net revenue of $4.28 billion decreased (11)% as reported, or (9)% in constant currency, compared to fiscal 2022. Organic, constant-currency net revenue decreased (11)% compared to FY'22. Q4'23 net loss of $(86) million and fiscal 2023 net loss of $(232) million. Q4'23 Adjusted EBITDA(1) of $139 million decreased (61)% as reported, or (61)% in constant currency, compared to Q4'22. Fiscal 2023 Adjusted EBITDA(1) of $714 million decreased (43)% as reported, or (42)% in constant c
Q3'23 net revenue of $1.04 billion decreased 19% as reported, or 17% in constant currency(1), compared to Q3'22. Organic, constant-currency net revenue decreased by 19%, compared to Q3'22. Q3'23 net loss of $(227) million, including a goodwill impairment of $210 million. Q3'23 Adjusted EBITDA(1) of $105 million decreased 69% as reported, or 68% in constant currency, compared to Q3'22. Updated FY'23 financial guidance projects net revenue of $4,225 million to $4,325 million and Adjusted EBITDA(1) of $700 million to $750 million. (1) See "Non-GAAP Financial Measures" below and the GAAP to non-GAAP reconciliation provided later in this release. Catalent, Inc. (NYSE:CTLT), the le
Catalent, Inc. ("Catalent" or the "Company") (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that, in light of the circumstances described in the Company's Notification of Late Filing on Form 12b-25 filed on May 11, 2023 (the "Form 12b-25") with the Securities and Exchange Commission (the "SEC"); the Company's ongoing focus on finalizing its financial statements and other disclosures in its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023 (the "Form 10-Q"); and completing its quarterly closing processes and procedures, it requires additional time to complete its preparation and review of its
Catalent, Inc. ("Catalent" or the "Company") (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that in light of the circumstances described in the Company's Form 12b-25 filed on May 11, 2023, with the Securities and Exchange Commission, and the Company's ongoing focus on finalizing its financial statements and other disclosures in its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023 (the "Form 10-Q") and completing its quarterly closing processes and procedures, it will be postponing the release of its financial results for the third quarter of fiscal year 2023, ended March 31, 2023, and the c
4 - Catalent, Inc. (0001596783) (Issuer)
4 - Catalent, Inc. (0001596783) (Issuer)
4 - Catalent, Inc. (0001596783) (Issuer)
4 - Catalent, Inc. (0001596783) (Issuer)
4 - Catalent, Inc. (0001596783) (Issuer)
4 - Catalent, Inc. (0001596783) (Issuer)
4 - Catalent, Inc. (0001596783) (Issuer)
4 - Catalent, Inc. (0001596783) (Issuer)
4 - Catalent, Inc. (0001596783) (Issuer)
4 - Catalent, Inc. (0001596783) (Issuer)
Robert W. Baird upgraded Catalent from Neutral to Outperform and set a new price target of $53.00 from $45.00 previously
Argus upgraded Catalent from Hold to Buy and set a new price target of $62.00
Wells Fargo initiated coverage of Catalent with a rating of Equal Weight and set a new price target of $43.00
JP Morgan resumed coverage of Catalent with a rating of Neutral and set a new price target of $45.00
Jefferies downgraded Catalent from Buy to Hold and set a new price target of $44.00 from $45.00 previously
JP Morgan downgraded Catalent from Overweight to Neutral and set a new price target of $45.00 from $90.00 previously
Deutsche Bank downgraded Catalent from Buy to Hold and set a new price target of $29.00 from $55.00 previously
BofA Securities downgraded Catalent from Neutral to Underperform and set a new price target of $28.00
Robert W. Baird downgraded Catalent from Outperform to Neutral and set a new price target of $53.00 from $82.00 previously
William Blair downgraded Catalent from Outperform to Mkt Perform
Adds three new directors with deep expertise across biopharma and life sciences Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings' ownership. Alessandro Maselli, President and CEO, and Board member of Catalent, said "I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech customers. Susan, Marie-France and Tim are each accomplished leaders who bring
NEW YORK, Dec. 18, 2024 /PRNewswire/ -- S&P MidCap 400 constituent Lennox International Inc. (NYSE:LII) will replace Catalent Inc. (NYSE:CTLT) in the S&P 500, and BILL Holdings Inc. (NYSE:BILL) will replace Lennox International in the S&P MidCap 400 effective prior to the opening of trading on Monday, December 23. Novo Holdings A/S has acquired Catalent in a deal that closed today, December 18. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 23, 2024 S&P 500 Addition Lennox International LII Industrials Dec 23, 2024 S&P 500 Deletion Catalent CTLT Health
Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T
GHENT, Belgium, June 6, 2024 /PRNewswire/ -- Ardena (the "Company") today announces the retirement of Harry Christiaens, PhD and the subsequent appointment of Jeremie Trochu as Chief Executive Officer. Jeremie is a seasoned executive in the pharmaceutical Contract Development and Manufacturing Operations (CDMO) industry. Harry will step down as CEO after 20 years of leading the Company, remaining on Ardena's Board. Jeremie brings an extensive knowledge of the life sciences and CDMO industry, and a proven track record of success in the biopharma sector, with 20 years of experience in building and growing businesses globally, expanding into new markets, and leading large-scale transformations
CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal
Traci Kyes and Makis Sigalas bring extensive industry experience to roles focused on expanding ViroCell's business in the US and Europe Team ViroCell will be attending the Cell & Gene Therapy Meeting on the Mesa, 10-12 October 2023 ViroCell Biologics ("ViroCell" or the "Company"), a specialist contract development and manufacturing organisation ("CDMO") in cell and gene therapy clinical trials, announces the appointment of Traci Kyes as Vice President (VP) of Business Development (US) and Makis Sigalas as Senior Business Development Director (Europe). Focused on driving growth in the US and Europe, respectively, Traci and Makis bring a wealth of business development expertise to ViroCel
Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that David McErlane has been named Group President of Catalent's Biologics segment, effective September 25, 2023. Mr. McErlane joins Catalent from Lonza, where he served as senior vice president and business unit head for Lonza's Bioscience business. Prior to joining Lonza, Mr. McErlane held several leadership positions at MilliporeSigma and BioReliance after beginning his career as an engineering manager at Zeneca. He holds a bachelor's degree in electronic systems engineering from Glasgow Caledonian University. "David is a seasoned and highly succe
Adding Four New Independent Directors Appoints John Greisch as Executive Chair Establishes New Strategic and Operational Review Committee of the Board Enters into Cooperation Agreement with Elliott Investment Management L.P. Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better biopharmaceutical treatments for patients worldwide, today announced several initiatives reflecting its ongoing commitment to strong corporate governance and shareholder value creation. The Nominating and Corporate Governance Committee of the Board has recommended, and the Board has approved, the appointment of four new independent directors: Steven Barg, Frank D'Amelio, St
Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that Lisa Evoli has been named Senior Vice President & Chief Human Resources Officer, effective immediately. Ms. Evoli joins Catalent from Integra Lifesciences, a global medical technology company based in Princeton, New Jersey. "Lisa is a proven leader with more than 25 years of experience achieving organizational results, building robust talent pipelines, and creating an inclusive and engaged workforce for a variety of multinational public companies," said Alessandro Maselli, President and Chief Executive Officer of Catalent. "Her deep health indus
Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that Matti Masanovich has been named Senior Vice President & Chief Financial Officer, effective July 5, 2023. Prior to joining Catalent, Mr. Masanovich served as Executive Vice President & Chief Financial Officer of Tenneco Automotive until it was acquired by Apollo. Previously he was Chief Financial Officer at Superior Industries International and General Cable Corporation. "Matti is a proven finance leader whose deep experience growing and driving profitability at publicly traded, complex global manufacturing companies is ideally suited to help Cat